AstraZeneca (LON:AZN)‘s stock had its “hold” rating reaffirmed by analysts at Shore Capital in a research report issued on Monday.
A number of other brokerages have also weighed in on AZN. UBS Group set a GBX 4,550 ($62.86) price objective on shares of AstraZeneca and gave the company a “neutral” rating in a report on Monday, January 8th. JPMorgan Chase & Co. set a GBX 5,500 ($75.99) price objective on shares of AstraZeneca and gave the company a “buy” rating in a report on Thursday, January 4th. Deutsche Bank reiterated a “buy” rating and set a GBX 5,700 ($78.75) price objective on shares of AstraZeneca in a report on Thursday, January 11th. BNP Paribas reiterated an “outperform” rating and set a GBX 5,800 ($80.13) price objective on shares of AstraZeneca in a report on Tuesday, January 16th. Finally, Jefferies Group reiterated a “hold” rating and set a GBX 5,500 ($75.99) price objective on shares of AstraZeneca in a report on Tuesday, January 16th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. AstraZeneca has an average rating of “Hold” and a consensus target price of GBX 5,199.70 ($71.84).
Shares of AstraZeneca (LON AZN) opened at GBX 4,783 ($66.08) on Monday. AstraZeneca has a twelve month low of GBX 4,260 ($58.86) and a twelve month high of GBX 5,520 ($76.26). The firm has a market cap of $60,570.00 and a PE ratio of 2,847.02.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.